Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Imipramine pamoate

Imipramine pamoate

Imipramine pamoate structure

Imipramine pamoate 

structure
  • CAS No:

    10075-24-8

  • Formula:

    C23H16O6.2C19H24N2

  • Chemical Name:

    Imipramine pamoate

  • Synonyms:

    2-Naphthalenecarboxylic acid,4,4′-methylenebis[3-hydroxy-,compd. with 10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine (1:2);2-Naphthoic acid,4,4′-methylenebis[3-hydroxy-,compd. with 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine (1:2);2-Naphthoic acid,4,4′-methylenebis[3-hydroxy-,compd. with 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine;5H-Dibenz[b,f]azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-,4,4′-methylenebis[3-hydroxy-2-naphthoate] (2:1);5H-Dibenz[b,f]azepine-5-propanamine,10,11-dihydro-N,N-dimethyl-,4,4′-methylenebis[3-hydroxy-2-naphthalenecarboxylate] (2:1);Imipramine pamoate;22540-17-6

Description

Imipramine Pamoate is the pamoate salt of imipramine, a synthetic dibenzazepine derivative with anti-depressant activity. Imipramine pamoate, a tricyclic antidepressant (TCA) potentiates the activity of adrenergic synapses by blocking the re-uptake of norepinephrine and serotonin, thereby preventing their degradation and increasing their availability. This drug also has antimuscarinic and anti-histamine properties, which contribute to its side effects.|The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.

Imipramine pamoate Basic Attributes

949.18400

948.48258577 g/mol

233-206-6

MC34P30298

DTXSID80143484

C61788

Characteristics

128.02000

12.27140

642.7ºC

356.5ºC

2.13E-17mmHg at 25°C

Safety Information

|Danger|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P260, P264, P270, P273, P301+P312, P307+P311, P321, P330, P391, P405, and P501|Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Drug Information

Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)|Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)

4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,f)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2)

Imipramine pamoate Use and Manufacturing

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:949.2
Hydrogen Bond Donor Count:4
Hydrogen Bond Acceptor Count:10
Rotatable Bond Count:12
Exact Mass:948.48258577
Monoisotopic Mass:948.48258577
Topological Polar Surface Area:128
Heavy Atom Count:71
Complexity:859
Covalently-Bonded Unit Count:3
Compound Is Canonicalized:Yes

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.